Alnylam Pharmaceuticals (ALNY) Free Cash Flow (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Free Cash Flow for 18 consecutive years, with $292.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Free Cash Flow rose 152.82% year-over-year to $292.0 million; the trailing twelve-month figure through Jun 2026 stood at $819.9 million (up 1150.99% YoY), and the FY2025 full-year result was $465.4 million, up 1192.73% from the prior year.
• Free Cash Flow climbed to $292.0 million in Q2 2026 per ALNY's latest filing, from $48.7 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $342.3 million in Q3 2023 and bottomed at -$189.1 million in Q1 2022.
• Historically, Free Cash Flow has averaged $10.7 million across 5 years, with a median of -$60.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow tumbled 130.04% in 2024, then surged 757.62% in 2025.
• Over 5 years, Free Cash Flow stood at -$153.6 million in 2022, then soared by 70.64% to -$45.1 million in 2023, then sank by 130.04% to -$103.8 million in 2024, then surged by 235.19% to $140.3 million in 2025, then soared by 108.21% to $292.0 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $292.0 million, $48.7 million, and $140.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.